BIOAVAILANT® is CellMedics’ multi-patented topical, transdermal, and ocular drug delivery platform that enables non-invasive delivery of biologics, proteins, peptides, antibodies, and other hard-to-deliver macromolecules.

The platform is based on a multi-mechanistic delivery architecture that combines a proprietary anhydrous vehicle with transport-enhancing compounds and formulation know-how. BIOAVAILANT® is designed to overcome key penetration, stability, and bioavailability limitations associated with conventional topical and transdermal systems, particularly for larger and more complex therapeutic molecules.

Unlike traditional small-molecule transdermal approaches, BIOAVAILANT® is being developed to support both local tissue delivery and systemic exposure across selected therapeutic applications. The platform has been evaluated in multiple translational settings, including ex vivo human skin studies, local tissue bioavailability studies, and preclinical systemic delivery models.

BIOAVAILANT® provides a differentiated, cream-based alternative to injections, infusions, microneedles, and device-assisted delivery for selected biologic and macromolecule programs. CellMedics is advancing the platform for internal development opportunities and external pharmaceutical partnering, with potential applications in immuno-oncology, dermatology, metabolic disease, ophthalmology, and inflammatory disorders.

Key Platform Features

• Non-invasive cream-based transdermal and ocular delivery
• Designed for biologics and macromolecules
• Supports targeted local tissue and systemic delivery
• Proprietary anhydrous formulation architecture
• Significantly enhances bioavailability vs. conventional topical systems
• Applicable to therapeutic areas where injection-free delivery offers significant clinical advantages